International Tax for Life Sciences, Healthcare & Pharmaceuticals
Updated: Aug 30
The science may progress through research, trials, regulatory approvals, manufacturing and commercialisation, while the tax model remains frozen at incorporation. When rights, researchers, trial activity, funding and regulatory risk sit in different countries, a generic IP licence cannot explain where value is created or how losses and future returns should be allocated.
Life sciences international tax across R&D, trials, licensing and commercialisation
This page is for biotech, medtech and pharmaceutical executives before a cross-border trial, licence, co-development deal, manufacturing scale-up, funding round or acquisition. The pressure usually arrives when a counterparty asks who owns the programme, who controlled the science and why each entity earns its return.
The commercial fault line a generic tax checklist can miss
The differentiator is the programme-control record: scientific decisions, clinical data, regulatory accountability, CRO activity, funding and IP rights are reconciled before a licence or transaction compresses them into one royalty percentage.
Warning signs inside the operating model
R&D funding and ownership are separated from the scientists and executives controlling the programme.
Clinical trials, investigators, CROs and regulatory work operate across countries without one cost and evidence map.
Manufacturing, quality, distribution and market-access functions are added after the IP model is documented.
Licences, milestones, royalties and co-development payments are negotiated without modelling source and withholding.
An acquisition or funding round requires a defensible history of IP ownership, R&D claims and intercompany charges.
None of these facts proves that the position is wrong. Each indicates that tax, contracts and operational evidence may be describing different economics—and that the difference may surface in cash, valuation, funding, audit or exit.
Life Sciences, Healthcare & Pharmaceuticals: the international tax decision chain
The map below connects the client's commercial gate to the ownership, cash-flow, people, contracting and evidence questions capable of changing after-tax value.
Decision gate | Commercial focus | International tax lens |
|---|---|---|
Discover | Research teams, grants, data and early rights | R&D eligibility, ownership, cost character and records |
Develop | Trials, CROs, regulatory and co-development | PE, services, withholding, cost sharing and evidence |
Manufacture | Scale-up, quality, supply and contract manufacturing | Asset ownership, inventory, customs and transfer pricing |
Commercialise | Licensing, distribution, market access and royalties | Source, royalty character, DEMPE and indirect tax |
Transact | Funding, partnering, acquisition or exit | Valuation, tax attributes, change of control and diligence |
Questions the board, investor, lender or tax authority may ask later
Who controls the development programme?
The decision record should show who controls scientific, regulatory and financial risk—not only which entity pays invoices or holds registrations.
How are trial and development costs characterised?
The answer can affect deductions, incentives, asset basis, loss use, intercompany charging and the after-tax cost of reaching approval.
What is being paid for?
Milestones, licences, data access, manufacturing, quality and support can carry different tax and withholding outcomes across countries.
Can the evidence survive a transaction?
IP assignments, researcher agreements, trial contracts, regulatory records, valuations and transfer-pricing files need to tell the same story.
What a decision-ready industry review should leave behind
A research-to-commercialisation ownership and funding map.
A clinical, regulatory and contract-manufacturing tax risk register.
A licensing, milestone and market-access cash-flow model.
A short implementation register naming the next decision, evidence owner and review trigger.
What to bring to the first working session
Bring the development plan, IP chain, CRO or trial contracts, funding history and proposed licence or transaction. The review can locate the value and evidence gaps before counterparties price them as risk.
Explore the wider cluster: International Tax Advice by Industry.
Primary sources and scope
These primary materials provide international-tax context. They do not determine the answer for a particular country, treaty, entity, contract or fact pattern.
OECD Transfer Pricing — the international arm's-length framework for related-party goods, services, financing and intangibles.
OECD Transfer Pricing Guidelines 2022 — functional analysis, comparability, documentation, intangibles and business restructurings.
ATO International Dealings Schedule instructions — Australian reporting context for international related-party dealings, financing and cross-border positions.
OECD guidance on transfer pricing aspects of intangibles — development, enhancement, maintenance, protection and exploitation of intangibles.
Australian Government Research and Development Tax Incentive — current Australian programme context for eligible R&D activities and expenditure.
Prepared by Extax Oceania for Australian and cross-border work. A named engagement lead and appropriately qualified project-country advisers are assigned after scope and conflicts are confirmed.
General information only—not a jurisdiction-specific tax opinion. Outcomes depend on the entities, contracts, people, assets, jurisdictions, domestic law, applicable treaties and regulatory requirements.
Extax Oceania | Ex Big 4 | International Tax | Technically updated 30 August 2026.
Comments